羟基脲对镰状细胞病胎儿血红蛋白合成的诱导作用。
Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease.
作者信息
Dover G J, Charache S
机构信息
Johns Hopkins University School of Medicine, Baltimore, MD.
出版信息
Semin Oncol. 1992 Jun;19(3 Suppl 9):61-6.
PMID:1379374
Abstract
In the past 8 years, it has become apparent that some cytotoxic drugs that interfere with DNA replication can reprogram erythroid progenitors to switch from adult hemoglobin to fetal hemoglobin (HbF) production. Hydroxyurea has now been shown to substantially increase HbF in patients with sickle cell anemia. Since HbF interferes with sickle hemoglobin polymerization, hydroxyurea may become an important therapeutic agent for patients with sickle cell anemia.
摘要
在过去8年中，显而易见的是，一些干扰DNA复制的细胞毒性药物能够对红系祖细胞进行重编程，使其从产生成人血红蛋白转变为产生胎儿血红蛋白（HbF）。现已证明，羟基脲可大幅提高镰状细胞贫血患者的HbF水平。由于HbF会干扰镰状血红蛋白的聚合，羟基脲可能会成为镰状细胞贫血患者的一种重要治疗药物。
Zotero 插件